Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

Multifaceted therapeutic potential of saponins in type 2 diabetes mellitus: mechanisms targeting insulin resistance and diabetic complications

Yuan Y., Shou KY., Wu SQ., Zhao JY., Liu Y., Wang YJ.

Narrative Review on Type 2 Diabetes, Chronic Kidney Disease, published in Front Pharmacol (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Front Pharmacol (2026)
Reported sample size
—
Source database
Europe PMC
PMID
42181864
PMCID
PMC13190208
DOI
10.3389/fphar.2026.1793697

Abstract (original English)

Background Type 2 diabetes mellitus (T2DM) is a complex metabolic disorder that poses management challenges due to the limited efficacy and adverse effects of current therapies. Saponins, a class of bioactive phytochemicals widely distributed in medicinal plants and other natural sources, exhibit antidiabetic activities through multi-target mechanisms, have emerged as promising therapeutic candidates for T2DM. This review systematically summarizes the pharmacological mechanisms and therapeutic potential of saponins in management of T2DM and its complications. Materials and methods Studies involving molecular, cellular, animal, and clinical studies of saponins in T2DM and its complications were screened and analyzed to provide a systematic overview. All the literature information in this review was collected from relevant literature published up to 2025 from the scientific databases, including PubMed, Web of Science, and China National Knowledge Infrastructure (CNKI). Results The pathogenesis of T2DM is characterized by insulin resistance, β-cell dysfunction, genetic susceptibility, gut microbiota dysbiosis, and metabolic disturbances, leading to hyperglycemia and systemic complications. This review demonstrates that saponins exert multifaceted antidiabetic effects through modulating key signaling pathways, including Keap1/Nrf2, AMPK/PI3K/Akt, and NF-κB. Furthermore, saponins de

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research